MARKET

RGEN

RGEN

Repligen
NASDAQ
193.40
-0.70
-0.36%
Closed 16:23 02/22 EST
OPEN
197.28
PREV CLOSE
194.10
HIGH
200.25
LOW
190.96
VOLUME
835.87K
TURNOVER
0
52 WEEK HIGH
211.13
52 WEEK LOW
110.45
MARKET CAP
10.80B
P/E (TTM)
262.24
1D
5D
1M
3M
1Y
5Y
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
NASDAQ · 21h ago
Repligen (RGEN) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Repligen (RGEN) The company's shares closed yesterday at $194.10. Arias covers the Healthcare sector and has a 40.45% success rate on recommended stocks. The analyst consensus is a Strong Buy with a price target of $207.
TipRanks · 23h ago
Repligen (RGEN) Receives a Buy from RBC Capital
TipRanks · 1d ago
What's Going On With Life Science-Focused Repligen Stock Today?
Repligen Corporation (NASDAQ:RGEN) reported fourth-quarter 2023 adjusted EPS of $0.33. The life science company reported sales of $155.74 million, down from $186.8 million a year ago. Repligen forecasts fiscal year 2024 revenue of $620 million-$650 million. The company's shares are down 0.40% at $198.93.
Benzinga · 1d ago
Health Care Sector Update for 02/21/2024: RGEN, IONS, BLCO, XLV, IBB
NASDAQ · 1d ago
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
NASDAQ · 1d ago
Repligen misses top-line and bottom-line estimates; initiates FY24 outlook
Repligen Corp. Misses Q4 revenue and bottom-line estimates; initiates FY24 outlook. Q4 non-GAAP EPS of $0.33 misses by $0 $0.01; revenue of $155.7M misses by 16.6% Y/Y. The company expects FY24 revenue to be $620 million to $650 million.
Seeking Alpha · 2d ago
Repligen Q4 Adjusted EPS $0.33, Inline, Sales $155.74M Beat $155.39M Estimate
Repligen reported quarterly earnings of $0.33 per share which met the analyst consensus estimate. The company reported quarterly sales of $155.74 million. This is a 16.61 percent decrease over sales of the same period last year. Repligen also reported a 51.47 percent decrease in sales for the quarter.
Benzinga · 2d ago
More
About RGEN
Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Webull offers Repligen Corp stock information, including NASDAQ: RGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGEN stock methods without spending real money on the virtual paper trading platform.